FolioLanternBeta
DYNDyne Therapeutics, Inc.

Douglas Kerr

Chief Medical Officer at Dyne Therapeutics, Inc., as of Sep 8, 2026Sold $233K of stock in the past 12 months: 100% under a disclosed plan.

Updated Oct 15, 2026 from SEC filings · covers Oct 16, 2025 to Oct 15, 2026
22%†
share of stake sold at Dyne Therapeutics, Inc.
† Measured against shares held at the start plus shares received, because most of the shares sold arrived during the period.
37K
shares held after the latest filing, Dyne Therapeutics, Inc.
Vested shares reported on Forms 3, 4 and 5 only. Not the insider's whole wealth.
1
company filed for

Selling by month

Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planOne dollar scale for every month; the tallest bar is labeled
OctNovDec 2025: $18K under a disclosed planDecJanFebMar 2026: $13K under a disclosed planMarAprMay 2026: $29K under a disclosed planMayJun 2026: $16K under a disclosed planJunJulAug 2026: $41K under a disclosed planAugSep 2026: $116K under a disclosed plan$116KSepOct

Pattern

What the filings show, past 12 months. Nothing here rates or predicts.

Roles from filings

Every company we track where this person has filed, newest filing first.

CompanyTitleFirst filingLatest filing
Dyne Therapeutics, Inc. (DYN)Chief Medical OfficerSep 3, 2024Sep 8, 2026

Recent filings

The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.

This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.